Elevance Health Inc

Elevance Health’s stock dips amid regulatory scrutiny—learn why the subpoena could reshape its valuation, risk profile, and competitive edge in U.S. health‑care insurance.

Institutional investors back Elevance Health amid Medicare policy uncertainty, highlighting strong balance sheet, value‑based care strategy, and attractive 12x P/E for potential upside.

Elevance Health Inc. will release Q1 2026 earnings at its January conference, with modest EPS growth expected and a $12.8 million settlement resolving residential‑treatment coverage denials—key insights for insurers, patients, and providers.

Elevance Health’s Q4 2025 earnings preview shows modest EPS and revenue growth, driven by cross‑benefit bundling and cost‑control, while facing telehealth and regulatory risks.

Elevance Health’s analyst upgrades boost target prices, spotlighting Medicare Advantage as a key growth driver amid rising regulatory scrutiny and market volatility.

Elevance Health’s rise amid CAQH’s takeover, scale pressure, and investor momentum: how data‑centric strategy can boost margins and outpace U.S. insurers.

Elevance Health’s new commentary explains how it’s reshaping employer‑, individual‑, Medicaid and Medicare plans with value‑based contracts, tiered networks and tech‑driven managed care to stay compliant, curb premiums and gain AM Best’s latest cred…

Elevance Health’s 2025 strategy: plan overhaul, rating downgrade insights, and Amy Schulman’s board boost—what it means for investors and future growth.

Elevance Health strengthens governance with former Pfizer GC Amy Schulman, boosts its credit rating per AM Best, and outlines a forward‑looking plan to improve patient care, digital services, and financial resilience in a rapidly evolving health‑car…

Elevance Health strengthens governance with former Pfizer counsel Amy Schulman on its board, boosting audit and finance oversight while expanding community maternal‑health initiatives and positioning for growth in the U.S. health‑insurance market.